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Olfactory ensheathing cells (OECs) have shown promising results for
patients with neurologic diseases in non‐double‐blind, placebo control
studies. Thirty patients with a unilateral ischemic stroke of more than a
year were enrolled in a phase 2, multicenter, randomized, double‐blind,
and placebo‐controlled cell therapy trial with a subsequent 12‐month
follow‐up. The primary therapeutic objective has shown that after 12
months, there were significant differences in National Institutes of
Health Stroke Scale (NIHSS), modified Rankin Scale (mRS) and Barthel
Index (BI) assessment scores among the OEC group, Schwann cell group
and placebo medium group at one‐year follow‐up. The second
therapeutic objective found that there were significant differences in
NIHSS, mRS, and BI assessment scores when comparing the endpoint
data with the baseline data in the OEC group. There was neither
hypersensitivity reaction nor adverse event. The results of this multicenter,
randomized, double‐blind, and placebo‐controlled study indicate that
injecting OECs into the olfactory sub‐mucosa have neurorestorative
effects, which can improve the quality of life for patients with chronic
ischemic strokes without serious side effects.
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Introduction

Stroke is the leading cause of adult disability
worldwide. Patients who have had an acute
ischemic stroke experience neurologic deficit
and suffer from functional disabilities even after
medical intervention, care, and rehabilitation [1].
The ability of the neurorestorative effects of
some cells have been investigated, and they
have shown promising results in patients with
acute, sub‐acute, and chronic stroke [1–5]. These
cells are transplanted into various sites in the
central nervous system (CNS), including the
parenchyma of the brain, cerebrospinal fluid
(CSF; ventricle, and subarachnoid space), vesicle
(intravenous or intra‐arterial), and areas above
combination [1, 2]. However, the majority of
these clinical cell therapy studies were small or
single center, phase 1 or/and 2, randomized, and
none of these studies have been double‐blind
and placebo‐controlled, or retrospective [2].
Despite the small number of studies, there
have been randomized, double‐blind, placebo‐
controlled clinical trials of cell therapies for
stroke [6–8]. Prasad et al. in 2014 reported a
multicenter, randomized trial with blinded
outcome assessment in which intravenous
autologous bone marrow mononuclear cell
therapy for sub‐acute ischemic stroke did not
show any beneficial effects [6]. Hess et al. in
2017 reported that a randomized, double‐blind,
placebo‐controlled, phase 2 trial of multi‐potent
adult progenitor cells derived from the bone
marrow for patients with acute ischemic stroke
failed to show any evidence of neurologic
recovery at day 90 in both the cell therapy and
placebo groups [7]. Savitz et al. in 2019 reported
a multicenter, randomized, blinded assessment,
sham‐controlled trial of autologous bone
marrow‐derived ALD‐401 cells infused through
the internal carotid artery of patients recovering
from an ischemic stroke did not show any
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difference in the primary therapeutic objective
between the groups [8]. Higher level and
evidence‐based studies of cell therapy for other
CNS diseases and trauma have also shown
negative results to date [9–12].
Our team has been engaged in clinical
research of olfactory ensheathing cells (OEC)
therapy for CNS diseases and damage since
2001. OECs have shown promising effects for
patients with chronic ischemic stroke in non‐
double‐blind or retrospective clinical studies [3,
13]. Previously, a double‐blind, placebo‐
controlled clinical cell therapy trial through
surgery was not approved by our hospital as the
procedure of cell or placebo medium
transplantation had the potential operational
risks and harm [3, 14, 15].
Danielyan et al. first reported that cells
following transnasal delivery in mice and rats
could (1) migrate into the olfactory bulb and
then to other parts of the brain, and; (2) enter the
CSF and move along the surface of the cortex
before entering the brain parenchyma [16]. In
this study, injecting cells into the olfactory
mucosa was performed via a minimally invasive
procedure and complied with ethical guidelines
[17]. This study was conducted in accordance
with the Chinese government’s regulations on
carrying out clinical studies of cell therapy
(National Health Commission, 2015 Document
No. 71).

2
2.1

Materials and methods
Study design

This study was a phase 2, multicenter,
randomized, double‐blind, placebo‐controlled
trial. The objectives of the study were to
determine if OECs had neurorestorative effects
in patients with an ischemic stroke in the
chronic phase (over 12 months), and whether
OEC transplantation into the olfactory mucosa
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via injection is safe. Schwann cells (SCs) were
the treatment control while the culture medium
was the placebo control in this study [18]. The
study was conducted in accordance with the
Declaration of Helsinki, and ethics approval was
obtained from the ethics committees of
participating hospitals. This study has been
registered in the Chinese Clinical Trial Registry
(ChiCTR1800014476).
2.2

Participants

The study recruited 30 participants (23 males
and 7 females) aged 40 to 70 years old (average
60.93 years). The participants were determined
using an inclusion criterion of having a chronic
ischemic stroke, and their medical records were
provided by the participating hospitals. The
participants were eligible for enrollment in the
study if they (1) had a unilateral stroke due to
carotid artery ischemia 12 months or more prior
to the time of enrollment, and their National
Institutes of Health Stroke Scale (NIHSS) scores
were between 4 to 25; (2) brain magnetic
resonance imaging (MRI) showed no other
neurologic disease except ischemic stroke; (3)
were fully conscious, cooperative with checkups,
with complete self‐control capacity, and were
willing and able to participate in the study’s
follow‐up and rehabilitation therapy (physical,
occupational, speech/language, or cognitive
rehabilitation therapy as needed) for 12 months.
Participants were excluded if they (1) were
comatose or initially had mild symptoms with
rapid degeneration or progressive stroke; (2)
had blood glucose < 2.7 mmol/L or > 22.2 mmol/L,
or blood pressure > 150/90 mmHg despite
appropriate treatment; (3) had heart, lung, liver,
or kidney failure, severe anemia, other severe
conditions, and/or mental illness; (4) were
unable to complete the 12‐month follow‐up; and
(5) if they were enrolled in other clinical trials or
did not sign the informed consent.

Participants were withdrawn from this study
if they (1) formally withdrew their signed
informed consent; (2) had complications
unrelated to the study which may affect the
results; (3) used unconventional drugs (such as
neurotropic factors, etc.); (4) had adverse
reactions not related to the study; (5) had other
serious medical conditions; (6) failed to adhere
to the rehabilitation schedule; (7) failed to
complete the follow‐ups, or (8) died from
unrelated causes. Data of drop‐outs were not
included in the final statistical analysis.
A written informed consent was obtained
either from the enrolled participant or a legal
representative of the participant after agreeing
to participate in this study.
2.3

Cell preparation and procedure

OEC preparation: OECs were derived from the
olfactory mucosa of an aborted fetus (received
approval and signed donation consent form)
and cultured in Dulbecco’s modified Eagle’s
medium (DMEM/F12; Gibco) with the
neurotrophic factors. Cells were allowed to
proliferate and differentiate according to the
methods of the patent (China patent ZL
201510516055.2. 2018.02.09) until the volume
was appropriate for clinical transplantation.
SC preparation: SCs were isolated from
human fetal sciatic nerve (received approval and
signed donation consent form). The specimens
were sliced, dissolved in trypsin (Invitrogen,
Carlsbad, CA, USA), and allowed to settle into a
monoplast suspension. These cells were
cultured in DMEM/F12 with 15% fetal bovine
serum (FBS, Hyclone) and harvested using
trypsin after 7 days [3].
OECs and SCs were visualized by immunos‐
taining p75 (over 85%) and S100 (over 90%) [3].
All cells used in this study were cultured and
prepared by the Third Medical Center and
General Hospital of PLA and Beijing Hongtianji
Journal of Neurorestoratology

Journal of Neurorestoratology

Neuroscience Academy, China.
Transplantation was carried out in the
procedure room of an otolaryngology clinic by
an otolaryngologist. Participants were instructed
to lay supine while a local mucosal anesthetic
was administered in the olfactory area 10–15
minutes before the procedure. A 0.3 mL cell
culture medium with or without cells was
injected into the olfactory sub‐mucosa of the
nasal septum between the superior and middle
turbinates (Figs. 1–3). The injected cells would
migrate into the olfactory bulb and into other
areas of the brain. They would then enter the
CSF, moving along the surface of the cortex
before entering the brain parenchyma [16]. Each
participant in the OEC group was injected with
5×106 OECs (in 0.3 mL medium) on each side of

Fig. 2
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the septum (total 10×106). Each participant in the
SC group was injected with 5×106 SCs (in 0.3 mL
medium) on each side of the septum, (total was
10×106). Each participant in the placebo group
was injected with cell culture medium (0.3 mL)
on each side of the septum.

Fig. 1 A otolaryngologist was preparing to do injection.

Before (A) and after (B) cell culture medium injecting into sub‐mucosa, local tissue looks plump.

Fig. 3 Diagram of cell injection and migration. After cell being injected into sub-mucosa of olfactory area, they migrated into olfactory
bulb and then to lesion area.
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2.4

Outcome

Assessments were conducted by physicians at
each participating hospital in this study. Prior to
the study, all physicians received training for
consistency and standardization of assessments.
Participants in all groups were assessed by
study personnel before treatment (baseline) and
at intervals of 1 month, 3 months, 6 months, and
12 months (endpoint). The NIHSS, modified
Rankin Scale (mRS), and Barthel Index (BI) were
also included in the assessment during each
follow‐up. Participants were allowed to contact
their physicians if they had any adverse events.
Inflammatory biomarkers together with heart,
pulmonary, renal, and hepatic functions were
taken at baseline and endpoint. MRI brain scans
were done at baseline and end point.
The primary objective was to determine
whether the change in assessment scores
between the groups was statistically significant.
The secondary objective was to determine
whether there was a significant difference in
assessment scores between the baseline and end
point in the OEC group.
The study would be discontinued if the
adverse events were serious enough to result in
either worsening of neurologic functions or
endangering the lives of enrolled patients.
2.5

Sample size

Our previous studies have shown a significant
difference in neurologic functional improvement
scores; self‐assessment of 10 patients before and
after treatment [3], and comparison between
OEC treatment and control treatments groups
with 6 and 8 [15] patients, respectively. Thus, we
recruited 30 participants for the study and they
were randomly assigned and divided into 3
groups of 10 participants per group.
2.6

Randomization

Through a computer‐generated process run by a

designated staff member in the cell processing
facility, the 30 participants were randomly
assigned in a natural order and in a 1:1:1 ratio to
receive either OECs (1/3), SCs (1/3) or placebo
(medium) (1/3). This designated staff member
was non‐blind to patient treatment assignments
and followed the treatment assignment
sequence list to prepare and dispense the
investigational product. This staff member had
no further involvement with the participants for
the rest of the study.
2.7

Blinding

Participants received a matching treatment
according to the generated sequence. The
injected media, with or without cells, have
similar color, and appearance. Participants,
investigators, and all study personnel (including
otolaryngologists, neurologists or rehabilitation
physicians) were blinded to the treatment
assignment.
2.8

Statistical analysis

Participants’ data were statistically analyzed. All
continuous variables were first examined by
Shapiro‐Wilk test to determine the normal
distribution. For normal continuous variables,
we used mean ± standard deviation to describe
variable characteristics, and then Levene’s test
was used to assess the assumption of
homogeneity of variances for these variables.
One‐way ANOVA was performed to assess
significant differences of the above variables in
different groups. For non‐normal variables,
results were expressed as median and
interquartile range. Kruskal‐Wallis test was
performed to assess any significant differences
among the groups. Dunn‐Bonferroni post hoc
test was used for all pairwise comparisons.
Chi‐Square was conducted to assess statistical
differences in categorical variables. Wilcoxon
signed‐rank test was used for evaluating the
Journal of Neurorestoratology
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intervention effect in different intervention
periods as compared to the baseline. P values
less than 0.05 were considered statistically
significant with two‐tailed tests.
Primary and secondary objectives were
analyzed in participants who completed follow‐
ups. Safety outcomes were analyzed in the
intention‐to‐treat population, which comprised
all participants who were randomly assigned to
receive cells or placebo treatment.
Statistical analyses were carried out by the
Statistical Package for the Social Sciences (SPSS)
version 26.0 (SPSS Inc., Chicago, IL, USA).

3

Results

3.1 Recruiting and randomly assigning patients
The study began to recruit participants on April
of 2017, and participants enrolled in the study

Fig. 4

Study flow diagram.
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had follow‐ups during a 12‐month period.
Thirty participants were recruited from 571
patients (350 from 960 Hospital of Chinese PLA,
160 from 981 Hospital of Chinese PLA, 23 from
Civil Aviation Guangzhou Hospital and 38 from
Taian Central Hospital, China). They were
equally divided and randomly assigned into
three groups (OEC, SC, placebo). One
participant in each group failed to finish the
study (Fig. 4).
3.2

Baseline characteristics

Demographic

and

clinical

information

of

baseline outcomes for all patients who received
OECs,

SCs,

or

placebo

treatment

was

summarized in Table 1. The groups were well
matched for age, history of stroke, median
NIHSS scores, median mRS scores, and median
BI scores.
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Table 1

Baseline characteristics.

Baseline characteristics

Placebo group (n = 9)

OEC group (n = 9)

SC group (n = 9)

63.56 ± 4.36

60.67 ± 4.53

56.89 ± 7.72

0.066

Sex, males
number (percentage)

5 (55.56%)

7 (77.78%)

8 (88.89%)

0.259

History of stroke in months

21.00 (13.00, 35.00)

27.00 (14.50, 52.00)

28.00 (18.50, 39.00)

0.643

5.00 (4.00, 6.50)

4.00 (4.00, 6.00)

5.00 (4.00, 11.50)

0.878

3.00 (2.00, 4.00)

3.00 (2.50, 4.00)

2.00 (1.50, 3.00)

0.243

85.00 (50.00, 90.00)

65.00 (47.50, 82.50)

90.00 (55.00, 92.50)

0.222

Age in years

P valuea

mean ± SD

median (IQR)
NIHSS score
median (IQR)
mRS score
median (IQR)
BI score
median (IQR)
a
Differences among control, OEC group and SC group were determined by one‐way ANOVA for age comparison in years.
Chi‐square test was used in sex comparison among three groups. Kruskal‐Wallis tests were used in non‐normal variables including
history of stroke, NIHSS score, mRS score and BI score. IQR, interquartile range；NIHSS, National Institutes of Health Stroke Scale;
mRS, modified Rankin Scale; BI, Barthel Index.

3.3

Primary objective results

Twenty‐seven participants in three groups who
finished the study were assessed for the primary
objective. Data analysis showed a significant
difference between baseline‐to‐end point
comparison and pairwise comparison, (between
OEC group with SC group or placebo group) in
Table 2

Comparison of changes in assessment scores at 12 months after treatment.

Assessment scores

a

NIHSS, mRS, and BI assessments at 12 months;
however, there was no significant difference
between the SC group and placebo group. Table
2 summarized those results. A significant
difference was already noted at 3 months (Table
3) which was more pronounced at 6months
(Table 4) and 12 months.

Placebo group (n = 9)

OEC group (n = 9)

SC group (n = 9)

Test statistic

P valuea

NIHSS, median (IQR)

0.00 (0.00, 0.00)

−3.00 (−4.50, −0.50)**

−1.00 (−2.00, 0.00)

8.842

0.012

mRS, median (IQR)

0.00 (0.00, 0.00)

−1.00 (−1.50, 0.00)

0.00 (0.00, 0.00)

6.693

0.035

BI, median (IQR)

0.00 (0.00, 0.00)

15.00 (2.50, 27.50)**

0.00 (0.00, 5.00)

10.509

0.005

#

Differences among placebo group, OEC group and SC group were determined by Kruskal‐Wallis. Dunn‐Bonferroni post hoc test

was used for all pairwise comparisons. ** Compared with placebo group, P < 0.01; # compared with OEC group, P < 0.05.
Table 3

a

Comparison of changes in assessment scores at 3 months after treatment.

Assessment scores

Placebo group (n = 9)

OEC group (n = 9)

SC group (n = 9)

Kruskal‐Wallis test statistic

P valuea

NIHSS, median (IQR)

0.00 (0.00, 0.00)

−1.00 (−2.50, 0.00)

0.00 (−0.50, 0.00)

4.953

0.084

mRS, median (IQR)

0.00 (0.00, 0.00)

0.00 (−0.50, 0.00)

0.00 (−0.50, 0.00)

0.473

0.789

BI, median (IQR)

0.00 (0.00, 0.00)

5.00 (0.00, 10.00)

0.00 (0.00, 0.00)#

9.296

0.010

Differences among placebo, OEC group and SC group were determined by Kruskal‐Wallis. Dunn‐Bonferroni post hoc test was

used for all pairwise comparisons. # Compared with OEC group, P < 0.05. No difference was found between placebo group and
OEC or SC group.
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Comparison of changes in assessment scores at 6 months after treatment.

Assessment scores

Placebo group (n = 9)

OEC group (n = 9)

SC group (n = 9)

Kruskal‐Wallis test statistic

P value a

NIHSS, median (IQR)

0.00 (0.00, 0.00)

−3.00 (−3.50, −0.50)**

−1.00 (−1.50, 0.00)

9.118

0.010

MRS, median (IQR)

0.00 (0.00, 0.00)

−1.00 (−1.50, 0.00)

0.00 (0.00, 0.00)

6.501

0.039

BI, median (IQR)

0.00 (0.00, 0.00)

15.00 (2.50, 27.50)**

0.00 (0.00, 2.50)#

12.241

0.002

Differences among placebo, OEC group and SC group were determined by Kruskal‐Wallis. Dunn‐Bonferroni post hoc test was
used for all pairwise comparisons. ** Compared with placebo group, P < 0.01; # compared with OEC group, P < 0.05.

a

3.4

Secondary objective results

the baseline. Table 5 summarizes these data. SC
treatment made limited changes (Table 6), while
placebo treatment did not show any changes
(Table 7) in assessments when comparing the
endpoint to the baseline.

Nine participants in the OEC group who
finished the study were assessed for the
secondary objective. Data analysis show
significant differences in NIHSS, mRS, and BI
assessments when comparing the endpoint with
Table 5

Neurorestorative effects in OEC treatment.
Baseline

Assessmen
t scores
NIHSS

mRS

BI

Median
(IQR)

1 month
Median
(IQR)

4.00

4.00

(4.00, 6.00)

(3.50, 6.00)

3.00

3.00

(2.50, 4.00)

(2.50, 4.00)

65.00

65.00

(47.50, 82.50)

(50.00, 82.50)

3 months
P
value
0.102

Median
(IQR)
4.00

6 months
P
value
0.042

(2.50, 5.50)
1.000

3.00

0.157

70.00

3.00

P
value
0.017

(2.00, 4.50)

(2.00, 3.50)
0.317

Median
(IQR)

1 year

2.00

0.034

0.038

85.00

3.00

P
value
0.018

(1.00, 4.50)

(2.00, 3.00)

(55.00, 85.00)

Median
(IQR)

2.00

0.038

(2.00, 3.00)
0.018

(72.50, 95.00)

85.00

0.018

(72.50, 95.00)

Differences between paired groups were determined Wilcoxon signed‐ranks test.
Table 6

Neurorestorative effects in SC treatment.
Baseline

Assessment
scores
NIHSS

mRS

BI

Median
(IQR)

1 month
Median
(IQR)

5.00

4.00

(4.00, 11.50)

(4.00, 11.50)

2.00

2.00

(1.50, 3.00)

(1.00, 3.00)

90.00

90.00

(55.00, 92.50)

(55.00, 92.50)

3 months
P
value
0.317

Median
(IQR)
4.00

6 months
P
value
0.157

(4.00, 11.50)
0.317

2.00

90.00

4.00

P
value
0.023

(3.00, 11.00)
0.157

(1.00, 3.00)
1.000

Median
(IQR)

1 year

2.00

(55.00, 92.50)

Differences between paired groups were determined Wilcoxon signed‐ranks test.

90.00
(55.00, 95.00)

4.00

P
value
0.024

(3.00, 11.00)
0.317

(1.00, 3.00)
1.000

Median
(IQR)

2.00

1.000

(1.00, 3.50)
0.157

95.00
(57.50, 95.00)

0.046
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Table 7

Neurorestorative effects in medium treatment.

Assessmen
t scores
NIHSS
mRS
BI

Baseline
Median
(IQR)

1 month
Median
(IQR)

5.00

5.00

(4.00, 6.50)

(4.00, 6.50)

3.00

3.00

(2.00, 4.00)

(2.00, 4.00)

85.00

85.00

(50.00, 90.00)

(50.00, 90.00)

3 months
P
Value
1.000

Median
(IQR)

6 months
P
Value

5.00

0.317

(4.00, 6.50)
1.000

5.00

P
Value
0.317

(4.00, 6.50)

3.00

0.317

(2.00, 3.50)
1.000

Median
(IQR)

One year

3.00

0.317

(50.00, 90.00)

85.00

5.00

P
Value
0.317

(4.00, 6.50)
0.317

(2.00, 3.50)

85.00

Median
(IQR)

3.00

0.317

(2.00, 3.50)
0.317

(50.00, 90.00)

85.00

0.317

(52.50, 90.00)

Differences between paired groups were determined Wilcoxon signed‐ranks test.

3.5

Safety and adverse events

There was no hypersensitivity reactions or
serious adverse events related to the study.
There were no adverse events recorded during
the procedure of injecting the treatment medium
into the olfactory sub‐mucosa. Brain MRI did
not show any structural changes when
comparing the end point to the baseline. No
tumors were found 12 months after treatment.

4

Discussion

The OEC is distinct from other glia as it has
characteristics of both SC and oligodendrocytes,
and it also has the ability to secrete neurotrophic
factors. OECs can migrate from the peripheral
nervous system to the CNS and play a
neurorestorative role by altering the micro‐
environment of lesions and stimulating
hibernating neurons for regeneration and repair.
In basic and pre‐clinical researches, the
neurorestorative mechanisms of OECs have been
shown to include neuroprotection, neuromodula‐
tion, neuroplasticity, neurogenesis, axonal
regeneration or sprouting, and, to some extent,
remyelination, angiogenesis, immunomodulation,
anti‐inflammation, and scar/cavity formation
[19, 20].
OECs support human olfactory tissue and
neurons by enabling regeneration in whole life

[21]. Based on previous clinical studies, OECs
have shown promising neurorestorative effects
for neurologic diseases and damage in a single
center, randomized control trial (RCT) [22],
randomized, non‐double‐blind studies [3, 14, 15],
and retrospective studies [13].
Previous studies using SCs alone [22–25] or in
conjunction with other kinds of cells [22, 26]
have shown limited neurorestorative effects in
patients with stroke, spinal cord injury, or other
neurologic diseases. In this study, SC treatment
has also shown limited neurorestorative effects
when comparing the endpoint to the baseline,
and there was no difference as compared to the
control group. We hypothesize that the reason
for the SC’s limited role in neurorestoration is
their restriction in migrating into the CNS [29].
At a higher level of evidence‐based medicine
(a multicenter, randomized, double‐blind, placebo‐
controlled clinical trial), this study is the first to
document the positive effects of OECs for
patients with chronic ischemic stroke. This
study has also shown that OECs appear to be
the support cells with the most potential to
restore damaged neurologic structures and
functions in the CNS.
The limitation of this study is the relatively
small sample size that may cause bias or
imprecise

results.

A

phase

3

trial

may

compensate for this shortcoming. Future clinical
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researches of OEC therapy for stroke should be

Financial support

directed toward an optimal dosage, a more
suitable

transplantation

route,

appropriate

therapeutic time window (our other clinical trial
of OECs for sub‐acute stroke is being carried out,

This trial received financial support from the
Chinese Association of Neurorestoratology
(CANR; Grant No. CANR‐2016‐1).

ChiCTR1800014497 [18]), and the effects of
repeated application. Additional multicenter,
randomized, double‐blind, placebo‐controlled
trials of OEC therapy should be performed for
other neurologic diseases and damage.

5

Conclusions

The study demonstrates that OEC therapy is
safe and can improve the quality of life for
patients with chronic ischemic stroke through
olfactory sub‐mucosa transplantation.
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